Aligos Therapeutics (ALGS) Capital Expenditures (2019 - 2023)

Aligos Therapeutics (ALGS) has reported Capital Expenditures for 5 consecutive years, with $7000.0 the latest figure, recorded in Q1 2023.

• For the quarter ending Q1 2023, Capital Expenditures fell 98.64% year-over-year to $7000.0; the trailing twelve-month figure through Mar 2023 stood at $435000.0 (down 60.45% YoY), and the FY2024 full-year result was $130000.0, up 584.21% from the prior year.
• Capital Expenditures eased to $7000.0 in Q1 2023 per ALGS's latest filing, from $91000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $1.1 million in Q1 2020 and bottomed at $3000.0 in Q3 2022.
• Historically, Capital Expenditures has averaged $330500.0 across 5 years, with a median of $320500.0 in 2021.
• The sharpest annual moves came in 2021 and 2023: Capital Expenditures jumped 450.82% in 2021, then slumped 98.64% in 2023.
• Over 5 years, Capital Expenditures stood at $721000.0 in 2019, then sank by 91.54% to $61000.0 in 2020, then surged by 450.82% to $336000.0 in 2021, then sank by 72.92% to $91000.0 in 2022, then slumped by 92.31% to $7000.0 in 2023.
• According to Business Quant data, Capital Expenditures over the past three periods registered $7000.0, $91000.0, and $3000.0 for Q1 2023, Q4 2022, and Q3 2022 respectively.